Amgen in talks with FDA over Epogen, Aranesp safety labels

12/7/2007 | Reuters

California-based Amgen said it is working with the FDA to decide whether to revise warning labels on anemia drugs Aranesp and Epogen, in view of two studies that reported more deaths and incidence of tumor growth in breast and cervical cancer patients taking the drugs. The treatments already carry "black box" warnings about their link to a higher risk of death, heart attack, stroke and cancer progression.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN